OncoSec Medical, Inc. (NASDAQ: ONCS) Starts Presentation at NobleCon13
OncoSec Medical (NASDAQ: ONCS) designs, develops and commercializes gene therapies, therapeutics and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead product candidate is the ImmunoPulse IL-12, which is in phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the company’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor. For more information, visit the company’s website at www.oncosec.com. About…